{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:14:30Z","timestamp":1791850470399,"version":"4.3.4"},"reference-count":232,"publisher":"Elsevier","isbn-type":[{"value":"9780443342929","type":"print"}],"license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002565","name":"Alzheimer's Drug Discovery Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002565","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U01AG076481"],"award-info":[{"award-number":["U01AG076481"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["RF1AG076912"],"award-info":[{"award-number":["RF1AG076912"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025]]},"DOI":"10.1016\/bs.apha.2024.10.004","type":"book-chapter","created":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T06:49:42Z","timestamp":1731048582000},"page":"103-157","source":"Crossref","is-referenced-by-count":15,"title":["Biological and therapeutic significance of targeting NLRP3 inflammasome in the brain and the current efforts to develop brain-penetrant inhibitors"],"prefix":"10.1016","author":[{"given":"Baljit","family":"Kaur","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Savannah","family":"Biby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jannatun N.","family":"Namme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayaji","family":"More","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiming","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shijun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/bs.apha.2024.10.004_bib1","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1038\/jcbfm.2008.143","article-title":"Inhibition of the inflammasome complex reduces the inflammatory response after thromboembolic stroke in mice","volume":"29","author":"Abulafia","year":"2009","journal-title":"Journal of Cerebral Blood Flow and Metabolism"},{"issue":"4","key":"10.1016\/bs.apha.2024.10.004_bib2","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1021\/acsmedchemlett.9b00433","article-title":"Discovery of N-cyano-sulfoximineurea derivatives as potent and orally bioavailable NLRP3 inflammasome inhibitors","volume":"11","author":"Agarwal","year":"2020","journal-title":"ACS Medicinal Chemistry Letters"},{"key":"10.1016\/bs.apha.2024.10.004_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfa.2024.134337","article-title":"Therapeutic cargo-free linalool-based nanoparticles attenuate inflammation by targeting NLRP3 inflammasome","volume":"697","author":"Ahmad","year":"2024","journal-title":"Colloids and Surfaces A: Physicochemical and Engineering Aspects"},{"issue":"3","key":"10.1016\/bs.apha.2024.10.004_bib4","doi-asserted-by":"crossref","first-page":"259","DOI":"10.31887\/DCNS.2004.6.3\/galexander","article-title":"Biology of Parkinson\u2019s disease: Pathogenesis and pathophysiology of a multisystem neurodegenerative disorder","volume":"6","author":"Alexander","year":"2004","journal-title":"Dialogues in Clinical Neuroscience"},{"issue":"6","key":"10.1016\/bs.apha.2024.10.004_bib5","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s11051-024-05983-8","article-title":"Advancements in neurotherapeutics: Nanoparticles overcoming the blood\u2013brain barrier for precise CNS targeting","volume":"26","author":"Alqudah","year":"2024","journal-title":"Journal of Nanoparticle Research"},{"key":"10.1016\/bs.apha.2024.10.004_bib6","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.trsl.2022.08.006","article-title":"NLRP3 inflammasome in neurodegenerative disease","volume":"252","author":"Anderson","year":"2023","journal-title":"Translational Research"},{"issue":"1","key":"10.1016\/bs.apha.2024.10.004_bib7","first-page":"1","article-title":"Plasma-borne indicators of inflammasome activity in Parkinson\u2019s disease patients","volume":"7","author":"Anderson","year":"2021","journal-title":"NPJ Parkinson\u2019s Disease"},{"issue":"20","key":"10.1016\/bs.apha.2024.10.004_bib8","doi-asserted-by":"crossref","first-page":"3473","DOI":"10.1182\/blood-2013-05-502229","article-title":"C3a modulates IL-1\u03b2 secretion in human monocytes by regulating ATP efflux and subsequent NLRP3 inflammasome activation","volume":"122","author":"Asgari","year":"2013","journal-title":"Blood"},{"issue":"45","key":"10.1016\/bs.apha.2024.10.004_bib9","doi-asserted-by":"crossref","first-page":"39528","DOI":"10.1074\/jbc.M111.278812","article-title":"Crystal structure of NALP3 protein pyrin domain (PYD) and its implications in inflammasome assembly","volume":"286","author":"Bae","year":"2011","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/bs.apha.2024.10.004_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.108595","article-title":"MCC950 in the treatment of NLRP3-mediated inflammatory diseases: Latest evidence and therapeutic outcomes","volume":"106","author":"Bakhshi","year":"2022","journal-title":"International Immunopharmacology"},{"issue":"3","key":"10.1016\/bs.apha.2024.10.004_bib11","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1002\/path.5846","article-title":"NLRP3 inflammasome as a key molecular target underlying cognitive resilience in amyotrophic lateral sclerosis","volume":"256","author":"Banerjee","year":"2022","journal-title":"The Journal of Pathology"},{"issue":"1","key":"10.1016\/bs.apha.2024.10.004_bib12","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s12974-022-02674-w","article-title":"Delayed NLRP3 inflammasome inhibition ameliorates subacute stroke progression in mice","volume":"20","author":"Bellut","year":"2023","journal-title":"Journal of Neuroinflammation"},{"issue":"10","key":"10.1016\/bs.apha.2024.10.004_bib13","doi-asserted-by":"crossref","first-page":"5323","DOI":"10.1016\/S0021-9258(18)83546-3","article-title":"A pre-aspartate-specific protease from human leukocytes that cleaves pro-interleukin-1 beta","volume":"264","author":"Black","year":"1989","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/bs.apha.2024.10.004_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2022.879021","article-title":"The NLRP3 inflammasome pathway: A review of mechanisms and inhibitors for the treatment of inflammatory diseases","volume":"14","author":"Blevins","year":"2022","journal-title":"Frontiers in Aging Neuroscience"},{"key":"10.1016\/bs.apha.2024.10.004_bib15","unstructured":"Bock, M. G., Harrison, D., & Scanlon, J. E. (2020). World Intellectual Property Organization Patent No. WO2020249664A1. Retrieved from https:\/\/patents.google.com\/patent\/WO2020249664A1\/de."},{"issue":"15","key":"10.1016\/bs.apha.2024.10.004_bib16","doi-asserted-by":"crossref","first-page":"5528","DOI":"10.1523\/JNEUROSCI.21-15-05528.2001","article-title":"Role of IL-1\u03b1 and IL-1\u03b2 in ischemic brain damage","volume":"21","author":"Boutin","year":"2001","journal-title":"The Journal of Neuroscience"},{"key":"10.1016\/bs.apha.2024.10.004_bib17","unstructured":"Brain Injury Facts. (n.d.). Retrieved October 14, 2024, from International Brain Injury Association website: https:\/\/www.internationalbrain.org\/resources\/brain-injury-facts."},{"issue":"11","key":"10.1016\/bs.apha.2024.10.004_bib18","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1038\/nrd3248","article-title":"Fingolimod (FTY720): Discovery and development of an oral drug to treat multiple sclerosis","volume":"9","author":"Brinkmann","year":"2010","journal-title":"Nature Reviews. Drug Discovery"},{"issue":"8","key":"10.1016\/bs.apha.2024.10.004_bib19","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1038\/ni.3202","article-title":"The receptor NLRP3 is a transcriptional regulator of TH2 differentiation","volume":"16","author":"Bruchard","year":"2015","journal-title":"Nature Immunology"},{"issue":"3","key":"10.1016\/bs.apha.2024.10.004_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41419-023-05672-9","article-title":"Alpha-synuclein in Parkinson\u2019s disease and other synucleinopathies: From overt neurodegeneration back to early synaptic dysfunction","volume":"14","author":"Calabresi","year":"2023","journal-title":"Cell Death & Disease"},{"issue":"1","key":"10.1016\/bs.apha.2024.10.004_bib21","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/fsn3.1324","article-title":"Therapeutic alternative of the ketogenic Mediterranean diet to improve mitochondrial activity in Amyotrophic Lateral Sclerosis (ALS): A comprehensive review","volume":"8","author":"Caplliure-Llopis","year":"2020","journal-title":"Food Science & Nutrition"},{"issue":"12","key":"10.1016\/bs.apha.2024.10.004_bib22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1002452","article-title":"Inflammasome-dependent pyroptosis and IL-18 protect against Burkholderia pseudomallei lung infection while IL-1\u03b2 is deleterious","volume":"7","author":"Ceballos-Olvera","year":"2011","journal-title":"PLoS Pathogens"},{"key":"10.1016\/bs.apha.2024.10.004_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2019.577089","article-title":"Inflammasome and \u03b1-synuclein in Parkinson\u2019s disease: A cross-sectional study","volume":"338","author":"Chatterjee","year":"2020","journal-title":"Journal of Neuroimmunology"},{"key":"10.1016\/bs.apha.2024.10.004_bib24","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.semcancer.2022.08.008","article-title":"Nanomedicines targeting the inflammasome as a promising therapeutic approach for cell senescence","volume":"86","author":"Chaturvedi","year":"2022","journal-title":"Seminars in Cancer Biology"},{"issue":"6","key":"10.1016\/bs.apha.2024.10.004_bib25","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1038\/s41423-021-00683-y","article-title":"RRx-001 ameliorates inflammatory diseases by acting as a potent covalent NLRP3 inhibitor","volume":"18","author":"Chen","year":"2021","journal-title":"Cellular & Molecular Immunology"},{"issue":"2","key":"10.1016\/bs.apha.2024.10.004_bib26","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1111\/jcmm.17104","article-title":"Immunoproteasome modulates NLRP3 inflammasome\u2010mediated neuroinflammation under cerebral ischaemia and reperfusion conditions","volume":"26","author":"Chen","year":"2022","journal-title":"Journal of Cellular and Molecular Medicine"},{"issue":"1","key":"10.1016\/bs.apha.2024.10.004_bib27","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s40478-016-0382-8","article-title":"Microglial neuroinflammation contributes to tau accumulation in chronic traumatic encephalopathy","volume":"4","author":"Cherry","year":"2016","journal-title":"Acta Neuropathologica Communications"},{"issue":"13","key":"10.1016\/bs.apha.2024.10.004_bib28","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1523\/JNEUROSCI.3045-16.2017","article-title":"HIV-1 tat primes and activates microglial NLRP3 inflammasome-mediated neuroinflammation","volume":"37","author":"Chivero","year":"2017","journal-title":"The Journal of Neuroscience: The Official Journal of the Society for Neuroscience"},{"issue":"12","key":"10.1016\/bs.apha.2024.10.004_bib29","doi-asserted-by":"crossref","first-page":"995","DOI":"10.3390\/cells13120995","article-title":"Elevated NLRP3 inflammasome activation is associated with motor neuron degeneration in ALS","volume":"13","author":"Cihankaya","year":"2024","journal-title":"Cells"},{"issue":"2","key":"10.1016\/bs.apha.2024.10.004_bib30","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1084\/jem.20170771","article-title":"B1a B cells require autophagy for metabolic homeostasis and self-renewal","volume":"215","author":"Clarke","year":"2018","journal-title":"The Journal of Experimental Medicine"},{"key":"10.1016\/bs.apha.2024.10.004_bib31","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1190219","article-title":"Divergent functional outcomes of NLRP3 blockade downstream of multi-inflammasome activation: Therapeutic implications for ALS","volume":"14","author":"Cl\u00e9net","year":"2023","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/bs.apha.2024.10.004_bib32","unstructured":"ClinicalTrials.gov. (n.d.). Retrieved July 29, 2024, from https:\/\/clinicaltrials.gov\/study\/NCT06097663?cond=NCT06097663&rank=1."},{"issue":"6","key":"10.1016\/bs.apha.2024.10.004_bib33","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/s41589-019-0277-7","article-title":"MCC950 directly targets the NLRP3 ATP-hydrolysis motif for inflammasome inhibition","volume":"15","author":"Coll","year":"2019","journal-title":"Nature Chemical Biology"},{"issue":"3","key":"10.1016\/bs.apha.2024.10.004_bib34","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/nm.3806","article-title":"A small molecule inhibitior of the NLRP3 inflammasome is a potential therapeutic for inflammatory diseases","volume":"21","author":"Coll","year":"2015","journal-title":"Nature Medicine"},{"key":"10.1016\/bs.apha.2024.10.004_bib35","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.bbi.2016.09.027","article-title":"Does neuroinflammation drive the relationship between tau hyperphosphorylation and dementia development following traumatic brain injury?","volume":"60","author":"Collins-Praino","year":"2017","journal-title":"Brain, Behavior, and Immunity"},{"issue":"6","key":"10.1016\/bs.apha.2024.10.004_bib36","first-page":"E961","article-title":"Active MLKL triggers the NLRP3 inflammasome in a cell-intrinsic manner","volume":"114","author":"Conos","year":"2017","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/bs.apha.2024.10.004_bib37","unstructured":"Cooper, M., Miller, D., Macleod, A., Shannon, J., Thom, S., Strutt, I., & Wiltenburg, J. V. (2022). Patent No. US20220106289A1. https:\/\/patents.google.com\/patent\/US20220106289A1\/en."},{"key":"10.1016\/bs.apha.2024.10.004_bib38","unstructured":"Cooper, M., Miller, D., Macleod, A., Thom, S., St-Gallay, S., Shannon, J., \u2026 Arregui, J. C. (2019). World Intellutual Property Organisation Patent No. WO2019034690A1."},{"key":"10.1016\/bs.apha.2024.10.004_bib39","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.nbd.2014.10.019","article-title":"Neuroinflammation and brain atrophy in former NFL players: An in vivo multimodal imaging pilot study","volume":"74","author":"Coughlin","year":"2015","journal-title":"Neurobiology of Disease"},{"key":"10.1016\/bs.apha.2024.10.004_bib40","unstructured":"Could an NLRP3 inhibitor be the one drug to conquer common diseases? (2020). Retrieved July 17, 2024, from Chemical & Engineering News website: https:\/\/cen.acs.org\/pharmaceuticals\/drug-discovery\/Could-an-NLRP3-inhibitor-be-the-one-drug-to-conquer-common-diseases\/98\/i7."},{"issue":"1","key":"10.1016\/bs.apha.2024.10.004_bib41","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12974-016-0477-y","article-title":"Activation of phagocytic activity in astrocytes by reduced expression of the inflammasome component ASC and its implication in a mouse model of Alzheimer disease","volume":"13","author":"Couturier","year":"2016","journal-title":"Journal of Neuroinflammation"},{"issue":"3","key":"10.1016\/bs.apha.2024.10.004_bib42","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.jaci.2010.12.006","article-title":"Mite allergen is a danger signal for the skin via activation of inflammasome in keratinocytes","volume":"127","author":"Dai","year":"2011","journal-title":"The Journal of Allergy and Clinical Immunology"},{"issue":"6","key":"10.1016\/bs.apha.2024.10.004_bib43","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/S0896-6273(03)00568-3","article-title":"Parkinson\u2019s disease: Mechanisms and models","volume":"39","author":"Dauer","year":"2003","journal-title":"Neuron"},{"issue":"24","key":"10.1016\/bs.apha.2024.10.004_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmb.2021.167309","article-title":"Crystal structure of NLRP3 NACHT domain with an inhibitor defines mechanism of inflammasome inhibition","volume":"433","author":"Dekker","year":"2021","journal-title":"Journal of Molecular Biology"},{"issue":"2","key":"10.1016\/bs.apha.2024.10.004_bib45","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1002\/glia.23728","article-title":"The microglial NLRP3 inflammasome is activated by amyotrophic lateral sclerosis proteins","volume":"68","author":"Deora","year":"2020","journal-title":"Glia"},{"issue":"10","key":"10.1016\/bs.apha.2024.10.004_bib46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41419-021-04240-3","article-title":"A long way to go: Caspase inhibitors in clinical use","volume":"12","author":"Dhani","year":"2021","journal-title":"Cell Death & Disease"},{"issue":"1","key":"10.1016\/bs.apha.2024.10.004_bib47","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.immuni.2018.04.032","article-title":"The TWIK2 Potassium Efflux Channel in Macrophages Mediates NLRP3 Inflammasome-induced Inflammation","volume":"49","author":"Di","year":"2018","journal-title":"Immunity"},{"key":"10.1016\/bs.apha.2024.10.004_bib48","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms11929","article-title":"ASC filament formation serves as a signal amplification mechanism for inflammasomes","volume":"7","author":"Dick","year":"2016","journal-title":"Nature Communications"},{"key":"10.1016\/bs.apha.2024.10.004_bib49","unstructured":"Empowering people affected by MS to live their best lives. (n.d.). Retrieved July 1, 2024, from National Multiple Sclerosis Society website: https:\/\/www.nationalmssociety.org."},{"issue":"2","key":"10.1016\/bs.apha.2024.10.004_bib50","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.molcel.2012.02.016","article-title":"Inflammasome-activated caspase 7 cleaves PARP1 to enhance the expression of a subset of NF-\u03baB target genes","volume":"46","author":"Erener","year":"2012","journal-title":"Molecular Cell"},{"key":"10.1016\/bs.apha.2024.10.004_bib51","unstructured":"EudraCT Number 2016\u2013000943-14\u2014Clinical trial results\u2014EU Clinical Trials Register. (n.d.). Retrieved July 17, 2024, from https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2016\u2013000943-14\/results."},{"key":"10.1016\/bs.apha.2024.10.004_bib52","unstructured":"Facts about TBI. (2024). Retrieved July 29, 2024, from Traumatic Brain Injury & Concussion website: https:\/\/www.cdc.gov\/traumatic-brain-injury\/data-research\/facts-stats\/index.html."},{"issue":"5","key":"10.1016\/bs.apha.2024.10.004_bib53","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1089\/neu.2020.7226","article-title":"In vivo detection of extracellular adenosine triphosphate in a mouse model of traumatic brain injury","volume":"38","author":"Faroqi","year":"2021","journal-title":"Journal of Neurotrauma"},{"key":"10.1016\/bs.apha.2024.10.004_bib54","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.bbi.2020.12.009","article-title":"The NLRP3 inflammasome drives inflammation in ischemia\/reperfusion injury after transient middle cerebral artery occlusion in mice","volume":"92","author":"Franke","year":"2021","journal-title":"Brain, Behavior, and Immunity"},{"issue":"12","key":"10.1016\/bs.apha.2024.10.004_bib55","doi-asserted-by":"crossref","first-page":"5412","DOI":"10.1021\/acs.jmedchem.8b00733","article-title":"Structural insights of benzenesulfonamide analogues as NLRP3 inflammasome inhibitors: Design, synthesis, and biological characterization","volume":"61","author":"Fulp","year":"2018","journal-title":"Journal of Medicinal Chemistry"},{"issue":"4","key":"10.1016\/bs.apha.2024.10.004_bib56","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.immuni.2016.01.012","article-title":"Human monocytes engage an alternative inflammasome pathway","volume":"44","author":"Gaidt","year":"2016","journal-title":"Immunity"},{"issue":"9","key":"10.1016\/bs.apha.2024.10.004_bib57","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1002\/art.22842","article-title":"Pattern of interleukin-1\u03b2 secretion in response to lipopolysaccharide and ATP before and after interleukin-1 blockade in patients with CIAS1 mutations","volume":"56","author":"Gattorno","year":"2007","journal-title":"Arthritis & Rheumatism"},{"issue":"5","key":"10.1016\/bs.apha.2024.10.004_bib58","doi-asserted-by":"crossref","first-page":"3708","DOI":"10.1002\/alz.13809","article-title":"2024 Alzheimer\u2019s disease facts and figures","volume":"20","author":"Gaugler","year":"2024","journal-title":"Alzheimer\u2019s & Dementia"},{"issue":"2","key":"10.1016\/bs.apha.2024.10.004_bib59","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1136\/ard.2007.082222","article-title":"Crystals of monosodium urate monohydrate enhance lipopolysaccharide-induced release of interleukin 1 beta by mononuclear cells through a caspase 1-mediated process","volume":"68","author":"Giamarellos-Bourboulis","year":"2009","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"3","key":"10.1016\/bs.apha.2024.10.004_bib60","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/S0006-291X(84)80190-4","article-title":"Alzheimer\u2019s disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein","volume":"120","author":"Glenner","year":"1984","journal-title":"Biochemical and Biophysical Research Communications"},{"issue":"1","key":"10.1016\/bs.apha.2024.10.004_bib61","doi-asserted-by":"crossref","DOI":"10.1155\/2008\/614345","article-title":"The NALP3\/cryopyrin\u2010inflammasome complex is expressed in LPS\u2010induced ocular inflammation","volume":"2008","author":"Gonz\u00e1lez-Ben\u00edtez","year":"2008","journal-title":"Mediators of Inflammation"},{"issue":"465","key":"10.1016\/bs.apha.2024.10.004_bib62","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aah4066","article-title":"Inflammasome inhibition prevents \u03b1-synuclein pathology and dopaminergic neurodegeneration in mice","volume":"10","author":"Gordon","year":"2018","journal-title":"Science Translational Medicine"},{"key":"10.1016\/bs.apha.2024.10.004_bib63","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1742-2094-3-5","article-title":"Interleukin-1 mediates Alzheimer and Lewy body pathologies","volume":"3","author":"Griffin","year":"2006","journal-title":"Journal of Neuroinflammation"},{"issue":"2","key":"10.1016\/bs.apha.2024.10.004_bib64","doi-asserted-by":"crossref","first-page":"974","DOI":"10.4049\/jimmunol.0904145","article-title":"NLRP3 plays a critical role in the development of experimental autoimmune encephalomyelitis by mediating Th1 and Th17 responses","volume":"185","author":"Gris","year":"2010","journal-title":"Journal of Immunology (Baltimore, Md.: 1950)"},{"issue":"7245","key":"10.1016\/bs.apha.2024.10.004_bib65","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/nature07965","article-title":"Syk kinase signalling couples to the Nlrp3 inflammasome for anti-fungal host defence","volume":"459","author":"Gross","year":"2009","journal-title":"Nature"},{"issue":"10","key":"10.1016\/bs.apha.2024.10.004_bib66","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1021\/acschemneuro.7b00124","article-title":"Development and characterization of a hydroxyl-sulfonamide analogue, 5-chloro-N-[2-(4-hydroxysulfamoyl-phenyl)-ethyl]-2-methoxy-benzamide, as a novel NLRP3 inflammasome inhibitor for potential treatment of multiple sclerosis","volume":"8","author":"Guo","year":"2017","journal-title":"ACS Chemical Neuroscience"},{"issue":"8","key":"10.1016\/bs.apha.2024.10.004_bib67","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/ni.1636","article-title":"The NALP3 inflammasome is involved in the innate immune response to amyloid-\u03b2","volume":"9","author":"Halle","year":"2008","journal-title":"Nature Immunology"},{"key":"10.1016\/bs.apha.2024.10.004_bib68","doi-asserted-by":"crossref","DOI":"10.1007\/s12035-024-04229-x","article-title":"Dysregulation of the Gut Microbiota Contributes to Sevoflurane-Induced Cognitive Dysfunction in Aged Mice by Activating the NLRP3 Inflammasome","author":"Han","year":"2024","journal-title":"Molecular Neurobiology"},{"key":"10.1016\/bs.apha.2024.10.004_bib69","doi-asserted-by":"crossref","first-page":"570711","DOI":"10.3389\/fneur.2020.570711","article-title":"The Role of Microglia and the Nlrp3 Inflammasome in Alzheimer\u2019s Disease","volume":"11","author":"Hanslik","year":"2020","journal-title":"Frontiers in Neurology"},{"issue":"8","key":"10.1016\/bs.apha.2024.10.004_bib70","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1021\/acsmedchemlett.2c00242","article-title":"Discovery and optimization of triazolopyrimidinone derivatives as selective NLRP3 inflammasome inhibitors","volume":"13","author":"Harrison","year":"2022","journal-title":"ACS Medicinal Chemistry Letters"},{"issue":"23","key":"10.1016\/bs.apha.2024.10.004_bib71","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2020.127560","article-title":"Discovery of a series of ester-substituted NLRP3 inflammasome inhibitors","volume":"30","author":"Harrison","year":"2020","journal-title":"Bioorganic & Medicinal Chemistry Letters"},{"issue":"6","key":"10.1016\/bs.apha.2024.10.004_bib72","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1021\/acschemneuro.1c00831","article-title":"Novel small-molecule inhibitor of NLRP3 inflammasome reverses cognitive impairment in an Alzheimer\u2019s disease model","volume":"13","author":"Haseeb","year":"2022","journal-title":"ACS Chemical Neuroscience"},{"key":"10.1016\/bs.apha.2024.10.004_bib73","unstructured":"Havrda, M. C. (2016). NLRP3 inflammasome in Parkinson\u2019s disease | Parkinson\u2019s disease. Retrieved July 1, 2024, from https:\/\/www.michaeljfox.org\/grant\/nlrp3-inflammasome-parkinsons-disease."},{"issue":"1","key":"10.1016\/bs.apha.2024.10.004_bib74","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1038\/s41467-018-04947-6","article-title":"Oridonin is a covalent NLRP3 inhibitor with strong anti-inflammasome activity","volume":"9","author":"He","year":"2018","journal-title":"Nature Communications"},{"issue":"10","key":"10.1016\/bs.apha.2024.10.004_bib75","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1038\/s41419-020-03072-x","article-title":"NLRP3-dependent microglial training impaired the clearance of amyloid-beta and aggravated the cognitive decline in Alzheimer\u2019s disease","volume":"11","author":"He","year":"2020","journal-title":"Cell Death & Disease"},{"issue":"7590","key":"10.1016\/bs.apha.2024.10.004_bib76","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/nature16959","article-title":"NEK7 is an essential mediator of NLRP3 activation downstream of potassium efflux","volume":"530","author":"He","year":"2016","journal-title":"Nature"},{"issue":"10","key":"10.1016\/bs.apha.2024.10.004_bib77","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.1301490","article-title":"Mitochondrial ROS induces NLRP3-dependent lysosomal damage and inflammasome activation","volume":"191","author":"Heid","year":"2013","journal-title":"Journal of Immunology (Baltimore, Md.: 1950)"},{"issue":"7434","key":"10.1016\/bs.apha.2024.10.004_bib78","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/nature11729","article-title":"NLRP3 is activated in Alzheimer\u2019s disease and contributes to pathology in APP\/PS1 mice","volume":"493","author":"Heneka","year":"2013","journal-title":"Nature"},{"issue":"10","key":"10.1016\/bs.apha.2024.10.004_bib79","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/s41583-018-0055-7","article-title":"Inflammasome signalling in brain function and neurodegenerative disease","volume":"19","author":"Heneka","year":"2018","journal-title":"Nature Reviews. Neuroscience"},{"issue":"12","key":"10.1016\/bs.apha.2024.10.004_bib80","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2020.127186","article-title":"Synthesis and evaluation of NLRP3-inhibitory sulfonylurea [11C]MCC950 in healthy animals","volume":"30","author":"Hill","year":"2020","journal-title":"Bioorganic & Medicinal Chemistry Letters"},{"issue":"2","key":"10.1016\/bs.apha.2024.10.004_bib81","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1002\/cpdd.1318","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of ZY-IL1 in three patients with cryopyrin-associated periodic syndromes","volume":"13","author":"Hissaria","year":"2024","journal-title":"Clinical Pharmacology in Drug Development"},{"issue":"7904","key":"10.1016\/bs.apha.2024.10.004_bib82","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/s41586-022-04467-w","article-title":"Structure of the NLRP3 decamer bound to the cytokine release inhibitor CRID3","volume":"604","author":"Hochheiser","year":"2022","journal-title":"Nature"},{"key":"10.1016\/bs.apha.2024.10.004_bib83","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1214289","article-title":"Cell type-specific roles of NLRP3, inflammasome-dependent and -independent, in host defense, sterile necroinflammation, tissue repair, and fibrosis","volume":"14","author":"Honda","year":"2023","journal-title":"Frontiers in Immunology"},{"issue":"4","key":"10.1016\/bs.apha.2024.10.004_bib84","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201708689","article-title":"Tranilast directly targets NLRP3 to treat inflammasome-driven diseases","volume":"10","author":"Huang","year":"2018","journal-title":"EMBO Molecular Medicine"},{"key":"10.1016\/bs.apha.2024.10.004_bib85","doi-asserted-by":"crossref","first-page":"1189008","DOI":"10.3389\/fcimb.2023.1189008","article-title":"Gut microbiota decreased inflammation induced by chronic unpredictable mild stress through affecting NLRP3 inflammasome","volume":"13","author":"Huang","year":"2023","journal-title":"Frontiers in Cellular and Infection Microbiology"},{"key":"10.1016\/bs.apha.2024.10.004_bib86","unstructured":"Inflazome\u2019s Somalix Demonstrates Positive Safety, Tolerability and Pharmacodynamic Profile in its Phase I Study. (2020, February 27). Retrieved July 17, 2024, from https:\/\/www.businesswire.com\/news\/home\/20200226006027\/en\/Inflazome%E2%80%99s-Somalix-Demonstrates-Positive-Safety-Tolerability-and-Pharmacodynamic-Profile-in-its-Phase-I-Study."},{"key":"10.1016\/bs.apha.2024.10.004_bib87","unstructured":"Initiation of Dosing Begins in Phase 1 Trial of VTX3232, an Innovative CNS-penetrant NLRP3 Inhibitor, by Ventyx Biosciences. (2023). Retrieved from https:\/\/www.pharmafocuseurope.com\/news\/initiation-of-dosing-begins-in-phase-1-trial-of-vtx3232."},{"issue":"26","key":"10.1016\/bs.apha.2024.10.004_bib88","doi-asserted-by":"crossref","first-page":"10480","DOI":"10.1073\/pnas.1201836109","article-title":"NLRP3 inflammasome induces chemotactic immune cell migration to the CNS in experimental autoimmune encephalomyelitis","volume":"109","author":"Inoue","year":"2012","journal-title":"Proceedings of the National Academy of Sciences"},{"key":"10.1016\/bs.apha.2024.10.004_bib89","doi-asserted-by":"crossref","first-page":"459","DOI":"10.3389\/fphar.2017.00459","article-title":"Lack of the Nlrp3 inflammasome improves mice recovery following traumatic brain injury","volume":"8","author":"Irrera","year":"2017","journal-title":"Frontiers in Pharmacology"},{"issue":"7784","key":"10.1016\/bs.apha.2024.10.004_bib90","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/s41586-019-1769-z","article-title":"NLRP3 inflammasome activation drives tau pathology","volume":"575","author":"Ising","year":"2019","journal-title":"Nature"},{"issue":"11","key":"10.1016\/bs.apha.2024.10.004_bib91","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1089\/neu.2017.5344","article-title":"MCC950, the selective inhibitor of nucleotide oligomerization domain-like receptor protein-3 inflammasome, protects mice against traumatic brain injury","volume":"35","author":"Ismael","year":"2018","journal-title":"Journal of Neurotrauma"},{"issue":"1","key":"10.1016\/bs.apha.2024.10.004_bib92","doi-asserted-by":"crossref","first-page":"5971","DOI":"10.1038\/s41598-018-24350-x","article-title":"Inhibition of the NLRP3-inflammasome as a potential approach for neuroprotection after stroke","volume":"8","author":"Ismael","year":"2018","journal-title":"Scientific Reports"},{"issue":"1","key":"10.1016\/bs.apha.2024.10.004_bib93","doi-asserted-by":"crossref","first-page":"7360","DOI":"10.1038\/ncomms8360","article-title":"Bruton\u2019s tyrosine kinase is essential for NLRP3 inflammasome activation and contributes to ischaemic brain injury","volume":"6","author":"Ito","year":"2015","journal-title":"Nature Communications"},{"issue":"47","key":"10.1016\/bs.apha.2024.10.004_bib94","doi-asserted-by":"crossref","first-page":"15811","DOI":"10.1523\/JNEUROSCI.4088-10.2010","article-title":"The inflammasome sensor, NLRP3, regulates CNS inflammation and demyelination via caspase-1 and interleukin-18","volume":"30","author":"Jha","year":"2010","journal-title":"Journal of Neuroscience"},{"issue":"12","key":"10.1016\/bs.apha.2024.10.004_bib95","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1002\/glia.22891","article-title":"NLRP3 inflammasome is expressed by astrocytes in the SOD1 mouse model of ALS and in human sporadic ALS patients","volume":"63","author":"Johann","year":"2015","journal-title":"Glia"},{"issue":"11","key":"10.1016\/bs.apha.2024.10.004_bib96","doi-asserted-by":"crossref","first-page":"3237","DOI":"10.1002\/art.27667","article-title":"Engagement of fatty acids with Toll-like receptor 2 drives interleukin-1\u03b2 production via the ASC\/caspase 1 pathway in monosodium urate monohydrate crystal-induced gouty arthritis","volume":"62","author":"Joosten","year":"2010","journal-title":"Arthritis and Rheumatism"},{"issue":"13","key":"10.1016\/bs.apha.2024.10.004_bib97","doi-asserted-by":"crossref","first-page":"9792","DOI":"10.1074\/jbc.M109.082305","article-title":"Anti-inflammatory compounds parthenolide and bay 11-7082 are direct inhibitors of the inflammasome","volume":"285","author":"Juliana","year":"2010","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/bs.apha.2024.10.004_bib98","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.mehy.2015.11.022","article-title":"In-situ expression of Interleukin-18 and associated mediators in the human brain of sALS patients: Hypothesis for a role for immune-inflammatory mechanisms","volume":"86","author":"Kadhim","year":"2016","journal-title":"Medical Hypotheses"},{"issue":"7371","key":"10.1016\/bs.apha.2024.10.004_bib99","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/nature10558","article-title":"Non-canonical inflammasome activation targets caspase-11","volume":"479","author":"Kayagaki","year":"2011","journal-title":"Nature"},{"key":"10.1016\/bs.apha.2024.10.004_bib100","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/197192b0","article-title":"Paired helical filaments in electron microscopy of Alzheimer\u2019s disease","volume":"197","author":"Kidd","year":"1963","journal-title":"Nature"},{"key":"10.1016\/bs.apha.2024.10.004_bib101","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2024.129622","article-title":"Structure-based design and synthesis of sulfonylureas as novel NLRP3 inhibitors for Alzheimer\u2019s disease","volume":"99","author":"Kim","year":"2024","journal-title":"Bioorganic & Medicinal Chemistry Letters"},{"issue":"11","key":"10.1016\/bs.apha.2024.10.004_bib102","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.1471","article-title":"A randomized, double-blind phase 1b study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of the NLRP3 inhibitor selnoflast in patients with moderate to severe active ulcerative colitis","volume":"13","author":"Klughammer","year":"2023","journal-title":"Clinical and Translational Medicine"},{"issue":"5","key":"10.1016\/bs.apha.2024.10.004_bib103","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1369\/jhc.6A7101.2006","article-title":"Inflammasome components NALP 1 and 3 show distinct but separate expression profiles in human tissues suggesting a site-specific role in the inflammatory response","volume":"55","author":"Kummer","year":"2007","journal-title":"Journal of Histochemistry & Cytochemistry"},{"issue":"2","key":"10.1016\/bs.apha.2024.10.004_bib104","doi-asserted-by":"crossref","first-page":"aag2045","DOI":"10.1126\/sciimmunol.aag2045","article-title":"ZBP1\/DAI is an innate sensor of influenza virus triggering the NLRP3 inflammasome and programmed cell death pathways","volume":"1","author":"Kuriakose","year":"2016","journal-title":"Science Immunology"},{"issue":"1","key":"10.1016\/bs.apha.2024.10.004_bib105","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s12974-019-1471-y","article-title":"A novel small molecular NLRP3 inflammasome inhibitor alleviates neuroinflammatory response following traumatic brain injury","volume":"16","author":"Kuwar","year":"2019","journal-title":"Journal of Neuroinflammation"},{"issue":"4","key":"10.1016\/bs.apha.2024.10.004_bib106","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.3233\/JAD-210400","article-title":"A novel inhibitor targeting NLRP3 inflammasome reduces neuropathology and improves cognitive function in Alzheimer\u2019s disease transgenic mice","volume":"82","author":"Kuwar","year":"2021","journal-title":"Journal of Alzheimer\u2019s Disease: JAD"},{"issue":"6","key":"10.1016\/bs.apha.2024.10.004_bib107","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/nri3452","article-title":"Activation and regulation of the inflammasomes","volume":"13","author":"Latz","year":"2013","journal-title":"Nature Reviews. Immunology"},{"key":"10.1016\/bs.apha.2024.10.004_bib108","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2020.01684","article-title":"TLR7 stimulation with imiquimod induces selective autophagy and controls Mycobacterium tuberculosis growth in mouse macrophages","volume":"11","author":"Lee","year":"2020","journal-title":"Frontiers in Microbiology"},{"issue":"7876","key":"10.1016\/bs.apha.2024.10.004_bib109","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/s41586-021-03875-8","article-title":"AIM2 forms a complex with pyrin and ZBP1 to drive PANoptosis and host defence","volume":"597","author":"Lee","year":"2021","journal-title":"Nature"},{"issue":"5","key":"10.1016\/bs.apha.2024.10.004_bib110","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1161\/STROKEAHA.118.023620","article-title":"Extent of ischemic brain injury after thrombotic stroke is independent of the NLRP3 (NACHT, LRR and PYD domains-containing protein 3) inflammasome","volume":"50","author":"Lemarchand","year":"2019","journal-title":"Stroke; a Journal of Cerebral Circulation"},{"issue":"6","key":"10.1016\/bs.apha.2024.10.004_bib111","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1007\/s00044-021-02740-7","article-title":"Discovery of N-phenyl-1-(phenylsulfonamido)cyclopropane-1-carboxamide analogs as NLRP3 inflammasome inhibitors","volume":"30","author":"Li","year":"2021","journal-title":"Medicinal Chemistry Research"},{"issue":"2","key":"10.1016\/bs.apha.2024.10.004_bib112","first-page":"209","article-title":"Early changes of NLRP3 inflammasome activation after hypoxic-ischemic brain injury in neonatal rats","volume":"14","author":"Li","year":"2021","journal-title":"International Journal of Clinical and Experimental Pathology"},{"issue":"21","key":"10.1016\/bs.apha.2024.10.004_bib113","doi-asserted-by":"crossref","first-page":"3908","DOI":"10.3390\/nano12213908","article-title":"Diverse Pathways of Engineered Nanoparticle-Induced NLRP3 Inflammasome Activation","volume":"12","author":"Liao","year":"2022","journal-title":"Nanomaterials"},{"key":"10.1016\/bs.apha.2024.10.004_bib114","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.expneurol.2017.01.005","article-title":"Omega-3 fatty acids regulate NLRP3 inflammasome activation and prevent behavior deficits after traumatic brain injury","volume":"290","author":"Lin","year":"2017","journal-title":"Experimental Neurology"},{"issue":"10","key":"10.1016\/bs.apha.2024.10.004_bib115","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1007\/s11064-013-1115-z","article-title":"Expression of the NLRP3 inflammasome in cerebral cortex after traumatic brain injury in a rat model","volume":"38","author":"Liu","year":"2013","journal-title":"Neurochemical Research"},{"issue":"20","key":"10.1016\/bs.apha.2024.10.004_bib116","doi-asserted-by":"crossref","first-page":"16955","DOI":"10.1074\/jbc.M112.358705","article-title":"Role of inflammasomes in host defense against Citrobacter rodentium infection","volume":"287","author":"Liu","year":"2012","journal-title":"The Journal of Biological Chemistry"},{"issue":"7610","key":"10.1016\/bs.apha.2024.10.004_bib117","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nature18629","article-title":"Inflammasome-activated gasdermin D causes pyroptosis by forming membrane pores","volume":"535","author":"Liu","year":"2016","journal-title":"Nature"},{"issue":"1","key":"10.1016\/bs.apha.2024.10.004_bib118","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1186\/s12974-018-1328-9","article-title":"Reduced gut microbiome protects from alcohol-induced neuroinflammation and alters intestinal and brain inflammasome expression","volume":"15","author":"Lowe","year":"2018","journal-title":"Journal of Neuroinflammation"},{"issue":"6","key":"10.1016\/bs.apha.2024.10.004_bib119","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1111\/jnc.14945","article-title":"Soluble A\u03b2 oligomers and protofibrils induce NLRP3 inflammasome activation in microglia","volume":"155","author":"Lu\u010di\u016bnait\u0117","year":"2020","journal-title":"Journal of Neurochemistry"},{"issue":"3","key":"10.1016\/bs.apha.2024.10.004_bib120","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1124\/pharmrev.122.000629","article-title":"Pharmacological inhibition of the NLRP3 inflammasome: Structure, molecular activation, and inhibitor-NLRP3 interaction","volume":"75","author":"Ma","year":"2023","journal-title":"Pharmacological Reviews"},{"issue":"2","key":"10.1016\/bs.apha.2024.10.004_bib121","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/ana.24070","article-title":"NLRP3 inflammasome contributes to inflammation after intracerebral hemorrhage","volume":"75","author":"Ma","year":"2014","journal-title":"Annals of Neurology"},{"key":"10.1016\/bs.apha.2024.10.004_bib122","unstructured":"Macleod, A., Shannon, J., Thom, S., Arregui, J. C., & Alanine, T. (2020). World Intellectual Property Organization Patent No. WO2020035466A1. Retrieved from https:\/\/patents.google.com\/patent\/WO2020035466A1\/en."},{"issue":"1","key":"10.1016\/bs.apha.2024.10.004_bib123","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/imr.12296","article-title":"Regulation of inflammasome activation","volume":"265","author":"Man","year":"2015","journal-title":"Immunological Reviews"},{"key":"10.1016\/bs.apha.2024.10.004_bib124","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2023.122062","article-title":"Nanovaccine that activates the NLRP3 inflammasome enhances tumor specific activation of anti-cancer immunity","volume":"296","author":"Manna","year":"2023","journal-title":"Biomaterials"},{"issue":"4","key":"10.1016\/bs.apha.2024.10.004_bib125","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1097\/FJC.0000000000000053","article-title":"A novel pharmacologic inhibitor of the NLRP3 inflammasome limits myocardial injury following ischemia-reperfusion in the mouse","volume":"63","author":"Marchetti","year":"2014","journal-title":"Journal of Cardiovascular Pharmacology"},{"issue":"7","key":"10.1016\/bs.apha.2024.10.004_bib126","first-page":"E1530","article-title":"OLT1177, a \u03b2-sulfonyl nitrile compound, safe in humans, inhibits the NLRP3 inflammasome and reverses the metabolic cost of inflammation","volume":"115","author":"Marchetti","year":"2018","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"11","key":"10.1016\/bs.apha.2024.10.004_bib127","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1089\/089771501317095250","article-title":"Monitoring of reactive oxygen species production after traumatic brain injury in rats with microdialysis and the 4-hydroxybenzoic acid trapping method","volume":"18","author":"Marklund","year":"2001","journal-title":"Journal of Neurotrauma"},{"issue":"8","key":"10.1016\/bs.apha.2024.10.004_bib128","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1007\/s11064-006-9120-0","article-title":"Energy metabolic changes in the early post-injury period following traumatic brain injury in rats","volume":"31","author":"Marklund","year":"2006","journal-title":"Neurochemical Research"},{"issue":"2","key":"10.1016\/bs.apha.2024.10.004_bib129","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S1097-2765(02)00599-3","article-title":"The inflammasome: A molecular platform triggering activation of inflammatory caspases and processing of proIL-beta","volume":"10","author":"Martinon","year":"2002","journal-title":"Molecular Cell"},{"key":"10.1016\/bs.apha.2024.10.004_bib130","unstructured":"Mayo Clinic Staff. (2021, February 4). Traumatic brain injury\u2014Symptoms & causes\u2014Mayo Clinic. Retrieved July 2, 2024, from https:\/\/www.mayoclinic.org\/diseases-conditions\/traumatic-brain-injury\/symptoms-causes\/syc-20378557."},{"key":"10.1016\/bs.apha.2024.10.004_bib131","unstructured":"Mayo Clinic Staff. (2024a, April 5). Parkinson\u2019s disease\u2014Symptoms and causes. Retrieved July 1, 2024, from Mayo Clinic website: https:\/\/www.mayoclinic.org\/diseases-conditions\/parkinsons-disease\/symptoms-causes\/syc-20376055."},{"key":"10.1016\/bs.apha.2024.10.004_bib132","unstructured":"Mayo Clinic Staff. (2024b, April 10). Amyotrophic lateral sclerosis (ALS)\u2014Symptoms and causes. Retrieved July 15, 2024, from Mayo Clinic website: https:\/\/www.mayoclinic.org\/diseases-conditions\/amyotrophic-lateral-sclerosis\/symptoms-causes\/syc-20354022."},{"issue":"21","key":"10.1016\/bs.apha.2024.10.004_bib133","doi-asserted-by":"crossref","first-page":"14721","DOI":"10.1021\/acs.jmedchem.2c01250","article-title":"Overcoming preclinical safety obstacles to discover (S)-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6-(methylamino)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide (GDC-2394): A potent and selective NLRP3 inhibitor","volume":"65","author":"McBride","year":"2022","journal-title":"Journal of Medicinal Chemistry"},{"issue":"7\u20138","key":"10.1016\/bs.apha.2024.10.004_bib134","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1080\/21678421.2023.2245858","article-title":"Prevalence of amyotrophic lateral sclerosis in the United States, 2018","volume":"24","author":"Mehta","year":"2023","journal-title":"Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration"},{"issue":"6","key":"10.1016\/bs.apha.2024.10.004_bib135","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/ni1344","article-title":"Cytoplasmic flagellin activates caspase-1 and secretion of interleukin 1beta via Ipaf","volume":"7","author":"Miao","year":"2006","journal-title":"Nature Immunology"},{"key":"10.1016\/bs.apha.2024.10.004_bib136","unstructured":"Mohan, R., Nuss, J., Harris, J., & Yuan, S. (2021). World Intellutual Organisation Property Patent No. WO2021188450A1. Retrieved from https:\/\/patents.google.com\/patent\/WO2021188450A1\/en?oq=WO2021188450A1."},{"issue":"5","key":"10.1016\/bs.apha.2024.10.004_bib137","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.3390\/ijms22052523","article-title":"Inflammasome in ALS skeletal muscle: NLRP3 as a potential biomarker","volume":"22","author":"Moreno-Garc\u00eda","year":"2021","journal-title":"International Journal of Molecular Sciences"},{"issue":"6","key":"10.1016\/bs.apha.2024.10.004_bib138","doi-asserted-by":"crossref","first-page":"575","DOI":"10.3892\/etm.2021.10007","article-title":"Massive efflux of adenosine triphosphate into the extracellular space immediately after experimental traumatic brain injury","volume":"21","author":"Moro","year":"2021","journal-title":"Experimental and Therapeutic Medicine"},{"issue":"9","key":"10.1016\/bs.apha.2024.10.004_bib139","doi-asserted-by":"crossref","first-page":"4678","DOI":"10.1039\/D3NR05570A","article-title":"Nanoparticle-mediated co-delivery of inflammasome inhibitors provides protection against sepsis","volume":"16","author":"Nandi","year":"2024","journal-title":"Nanoscale"},{"issue":"8","key":"10.1016\/bs.apha.2024.10.004_bib140","doi-asserted-by":"crossref","first-page":"6250","DOI":"10.1021\/acs.jmedchem.2c00149","article-title":"Synthesis and pharmacological evaluation of new N-sulfonylureas as NLRP3 inflammasome inhibitors: Identification of a hit compound to treat gout","volume":"65","author":"Narros-Fern\u00e1ndez","year":"2022","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/bs.apha.2024.10.004_bib141","unstructured":"National ALS Registry Dashboard | Amyotrophic Lateral Sclerosis (ALS) | CDC. (2024, July 10). Retrieved July 23, 2024, from https:\/\/www.cdc.gov\/als\/dashboard\/index.html."},{"issue":"5","key":"10.1016\/bs.apha.2024.10.004_bib142","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1111\/jcmm.12804","article-title":"Role of nucleotide-binding oligomerization domain 1 (NOD1) in pericyte-mediated vascular inflammation","volume":"20","author":"Navarro","year":"2016","journal-title":"Journal of Cellular and Molecular Medicine"},{"issue":"10","key":"10.1016\/bs.apha.2024.10.004_bib143","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1212\/WNL.0000000000007044","article-title":"A new way to estimate neurologic disease prevalence in the United States","volume":"92","author":"Nelson","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/bs.apha.2024.10.004_bib144","unstructured":"NodThera Announces Positive Phase 1 Study Readouts for the NLRP3 Inflammasome Inhibitors NT-0796 and NT-0249. (2022). Retrieved July 24, 2024, from Nodthera website: https:\/\/www.nodthera.com\/news\/nodthera-announces-positive-phase-1-study-readouts-for-the-nlrp3-inflammasome-inhibitors-nt-0796-and-nt-0249\/."},{"key":"10.1016\/bs.apha.2024.10.004_bib145","unstructured":"NodThera\u2019s NLRP3 Inhibitor NT-0796 Reverses Neuroinflammation in Parkinson\u2019s Disease Phase Ib\/IIa Trial. (2022). Retrieved July 24, 2024, from Nodthera website: https:\/\/www.nodthera.com\/news\/nodtheras-nlrp3-inhibitor-nt-0796-reverses-neuroinflammation-in-parkinsons-disease-phase-ib-iia-trial\/."},{"key":"10.1016\/bs.apha.2024.10.004_bib146","unstructured":"O\u2019Neill, L., Coll, R., Cooper, M., Robertson, A., & Schroder, K. (2016). World Intellectual Property Organisation Patent No. WO2016131098A1. Retrieved from https:\/\/patents.google.com\/patent\/WO2016131098A8\/en."},{"key":"10.1016\/bs.apha.2024.10.004_bib147","unstructured":"O\u2019Neill, L., Coll, R., Cooper, M., Robertson, A., Schroder, K., Murray Macleod, A., & Miller, D. (2017). World Intellutual Property Organisation Patent No. WO2017140778A1. Retrieved from https:\/\/patents.google.com\/patent\/WO2017140778A1\/en."},{"issue":"11","key":"10.1016\/bs.apha.2024.10.004_bib148","doi-asserted-by":"crossref","first-page":"4591","DOI":"10.1007\/s10967-023-09171-1","article-title":"Radiosynthesis of [11C]MNS for PET imaging of NLRP3 inflammasome with [11C]nitromethane in one-pot and its evaluation in rat brains","volume":"332","author":"Ogata","year":"2023","journal-title":"Journal of Radioanalytical and Nuclear Chemistry"},{"issue":"11","key":"10.1016\/bs.apha.2024.10.004_bib149","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2121353119","article-title":"Structural basis for the oligomerization-mediated regulation of NLRP3 inflammasome activation","volume":"119","author":"Ohto","year":"2022","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"9","key":"10.1016\/bs.apha.2024.10.004_bib150","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1089\/neu.2012.2650","article-title":"Inflammatory consequences in a rodent model of mild traumatic brain injury","volume":"30","author":"Perez-Polo","year":"2013","journal-title":"Journal of Neurotrauma"},{"issue":"6","key":"10.1016\/bs.apha.2024.10.004_bib151","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1002\/glia.23970","article-title":"\u03b1\u2010Synuclein evokes NLRP3 inflammasome\u2010mediated IL\u20101\u03b2 secretion from primary human microglia","volume":"69","author":"Pike","year":"2021","journal-title":"Glia"},{"key":"10.1016\/bs.apha.2024.10.004_bib152","unstructured":"Pipeline\u2014Ventus Therapeutics. (2023). Retrieved July 29, 2024, from Ventus Therapeutics website: https:\/\/www.ventustx.com\/pipeline\/pipeline\/.."},{"issue":"5321","key":"10.1016\/bs.apha.2024.10.004_bib153","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1126\/science.276.5321.2045","article-title":"Mutation in the \u03b1-synuclein gene identified in families with Parkinson\u2019s disease","volume":"276","author":"Polymeropoulos","year":"1997","journal-title":"Science (New York, N. Y.)"},{"issue":"6","key":"10.1016\/bs.apha.2024.10.004_bib154","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.4049\/jimmunol.1600035","article-title":"Efficacy and pharmacology of the NLRP3 inflammasome inhibitor CP-456,773 (CRID3) in murine models of dermal and pulmonary inflammation","volume":"197","author":"Primiano","year":"2016","journal-title":"The Journal of Immunology"},{"key":"10.1016\/bs.apha.2024.10.004_bib155","unstructured":"Qian, W., Liao, Y., Wei, C., Xi, Z., Xiao, Y., & Chen, S. (2021). World Intellutual Property Organisation Patent No. WO2021249337A1. Retrieved from https:\/\/patents.google.com\/patent\/WO2021249337A1\/en?oq=WO2021249337A1."},{"issue":"6","key":"10.1016\/bs.apha.2024.10.004_bib156","doi-asserted-by":"crossref","first-page":"4292","DOI":"10.1007\/s12035-016-9980-5","article-title":"Caspase-1 deficiency alleviates dopaminergic neuronal death via inhibiting caspase-7\/AIF pathway in MPTP\/p mouse model of Parkinson\u2019s disease","volume":"54","author":"Qiao","year":"2017","journal-title":"Molecular Neurobiology"},{"issue":"9","key":"10.1016\/bs.apha.2024.10.004_bib157","doi-asserted-by":"crossref","first-page":"4167","DOI":"10.1128\/JVI.01687-10","article-title":"The NLRP3 inflammasome detects encephalomyocarditis virus and vesicular stomatitis virus infection","volume":"85","author":"Rajan","year":"2011","journal-title":"Journal of Virology"},{"key":"10.1016\/bs.apha.2024.10.004_bib158","first-page":"1","article-title":"NLRP3 inflammasome: A key player in the pathogenesis of life-style disorders","author":"Ramachandran","year":"2024","journal-title":"Experimental & Molecular Medicine"},{"issue":"3","key":"10.1016\/bs.apha.2024.10.004_bib159","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.cell.2012.07.007","article-title":"TRIF licenses caspase-11-dependent NLRP3 inflammasome activation by gram-negative bacteria","volume":"150","author":"Rathinam","year":"2012","journal-title":"Cell"},{"issue":"sup1","key":"10.1016\/bs.apha.2024.10.004_bib160","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3109\/21678421.2013.778548","article-title":"Deciphering amyotrophic lateral sclerosis: What phenotype, neuropathology and genetics are telling us about pathogenesis","volume":"14","author":"Ravits","year":"2013","journal-title":"Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration"},{"issue":"S1","key":"10.1016\/bs.apha.2024.10.004_bib161","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1002\/ana.21543","article-title":"Current hypotheses for the underlying biology of amyotrophic lateral sclerosis","volume":"65","author":"Rothstein","year":"2009","journal-title":"Annals of Neurology"},{"key":"10.1016\/bs.apha.2024.10.004_bib162","unstructured":"Roush, W., Venkatraman, S., Ghosh, S., Shen, D.-M., Katz, J., & Seidel, H. M. (2020). World Intellectual Property Organization Patent No. WO2020086732A1. Retrieved from https:\/\/patents.google.com\/patent\/WO2020086732A1\/en%E2%80%8B%E2%80%8B%E2%80%8B."},{"issue":"22","key":"10.1016\/bs.apha.2024.10.004_bib163","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1056\/NEJM200105313442207","article-title":"Amyotrophic lateral sclerosis","volume":"344","author":"Rowland","year":"2001","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1016\/bs.apha.2024.10.004_bib164","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0010008","article-title":"Aspergillus fumigatus stimulates the NLRP3 inflammasome through a pathway requiring ROS production and the Syk tyrosine kinase","volume":"5","author":"Sa\u00efd-Sadier","year":"2010","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/bs.apha.2024.10.004_bib165","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1021\/acsmedchemlett.6b00198","article-title":"Identification, synthesis, and biological evaluation of the major human metabolite of NLRP3 inflammasome inhibitor MCC950","volume":"7","author":"Salla","year":"2016","journal-title":"ACS Medicinal Chemistry Letters"},{"key":"10.1016\/bs.apha.2024.10.004_bib166","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13024-016-0088-1","article-title":"The NLRP3 and NLRP1 inflammasomes are activated in Alzheimer\u2019s disease","volume":"11","author":"Saresella","year":"2016","journal-title":"Molecular Neurodegeneration"},{"issue":"2","key":"10.1016\/bs.apha.2024.10.004_bib167","doi-asserted-by":"crossref","first-page":"599","DOI":"10.2353\/ajpath.2006.060002","article-title":"Alzheimer\u2019s disease-like tau neuropathology leads to memory deficits and loss of functional synapses in a novel mutated tau transgenic mouse without any motor deficits","volume":"169","author":"Schindowski","year":"2006","journal-title":"The American Journal of Pathology"},{"issue":"1","key":"10.1016\/bs.apha.2024.10.004_bib168","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1074\/jbc.C115.700492","article-title":"A genome-wide CRISPR (clustered regularly interspaced short palindromic repeats) screen identifies NEK7 as an essential component of NLRP3 inflammasome activation","volume":"291","author":"Schmid-Burgk","year":"2016","journal-title":"The Journal of Biological Chemistry"},{"issue":"6","key":"10.1016\/bs.apha.2024.10.004_bib169","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.cell.2010.01.040","article-title":"The inflammasomes","volume":"140","author":"Schroder","year":"2010","journal-title":"Cell"},{"issue":"4537","key":"10.1016\/bs.apha.2024.10.004_bib170","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1126\/science.6120571","article-title":"Alzheimer\u2019s disease: Insolubility of partially purified paired helical filaments in sodium dodecyl sulfate and urea","volume":"215","author":"Selkoe","year":"1982","journal-title":"Science (New York, N. Y.)"},{"key":"10.1016\/bs.apha.2024.10.004_bib171","unstructured":"Selnoflast | ALZFORUM. (n.d.). Retrieved August 16, 2024, from https:\/\/www.alzforum.org\/therapeutics\/selnoflast."},{"issue":"7761","key":"10.1016\/bs.apha.2024.10.004_bib172","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/s41586-019-1295-z","article-title":"Structural mechanism for NEK7-licensed activation of NLRP3 inflammasome","volume":"570","author":"Sharif","year":"2019","journal-title":"Nature"},{"issue":"0","key":"10.1016\/bs.apha.2024.10.004_bib173","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0197-0186(01)00041-9","article-title":"Interleukin-1 promotion of MAPK-p38 overexpression in experimental animals and in Alzheimer\u2019s disease: Potential significance for tau protein phosphorylation.","volume":"39","author":"Sheng","year":"2001","journal-title":"Neurochemistry International"},{"issue":"3","key":"10.1016\/bs.apha.2024.10.004_bib174","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1038\/ni.3333","article-title":"NLRP3 activation and mitosis are mutually exclusive events coordinated by NEK7, a new inflammasome component","volume":"17","author":"Shi","year":"2016","journal-title":"Nature Immunology"},{"issue":"6645","key":"10.1016\/bs.apha.2024.10.004_bib175","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/42166","article-title":"\u03b1-Synuclein in Lewy bodies","volume":"388","author":"Spillantini","year":"1997","journal-title":"Nature"},{"issue":"1","key":"10.1016\/bs.apha.2024.10.004_bib176","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/ni.2477","article-title":"Capillary and arteriolar pericytes attract innate leukocytes exiting through venules and \u201cinstruct\u201d them with pattern-recognition and motility programs","volume":"14","author":"Stark","year":"2013","journal-title":"Nature Immunology"},{"key":"10.1016\/bs.apha.2024.10.004_bib177","unstructured":"Stroke Facts & Statistics. (2023). Retrieved July 29, 2024, from Stroke Awareness Foundation website: https:\/\/www.strokeinfo.org\/stroke-facts-statistics\/."},{"key":"10.1016\/bs.apha.2024.10.004_bib178","unstructured":"Stroke Overview | National Institute of Neurological Disorders and Stroke. (n.d.). Retrieved July 29, 2024, from https:\/\/www.ninds.nih.gov\/health-information\/stroke\/stroke-overview."},{"key":"10.1016\/bs.apha.2024.10.004_bib179","unstructured":"Stroke\u2014Symptoms and causes. (n.d.). Retrieved July 29, 2024, from Mayo Clinic website: https:\/\/www.mayoclinic.org\/diseases-conditions\/stroke\/symptoms-causes\/syc-20350113."},{"key":"10.1016\/bs.apha.2024.10.004_bib180","unstructured":"Stroke\u2014What Is a Stroke? | NHLBI, NIH. (2023, May 26). Retrieved July 29, 2024, from https:\/\/www.nhlbi.nih.gov\/health\/stroke."},{"issue":"2","key":"10.1016\/bs.apha.2024.10.004_bib181","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/0304-3940(88)90080-8","article-title":"Preamyloid deposits in the cerebral cortex of patients with Alzheimer\u2019s disease and nondemented individuals","volume":"93","author":"Tagliavini","year":"1988","journal-title":"Neuroscience Letters"},{"issue":"3","key":"10.1016\/bs.apha.2024.10.004_bib182","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s12035-013-8475-x","article-title":"The NLRP3 inflammasome in Alzheimer\u2019s disease","volume":"48","author":"Tan","year":"2013","journal-title":"Molecular Neurobiology"},{"issue":"9","key":"10.1016\/bs.apha.2024.10.004_bib183","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1111\/cts.13576","article-title":"First\u2010in\u2010human phase 1 trial evaluating safety, pharmacokinetics, and pharmacodynamics of NLRP3 inflammasome inhibitor, GDC\u20102394, in healthy volunteers","volume":"16","author":"Tang","year":"2023","journal-title":"Clinical and Translational Science"},{"issue":"1","key":"10.1016\/bs.apha.2024.10.004_bib184","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/s41467-017-00227-x","article-title":"CLICs-dependent chloride efflux is an essential and proximal upstream event for NLRP3 inflammasome activation","volume":"8","author":"Tang","year":"2017","journal-title":"Nature Communications"},{"issue":"38","key":"10.1016\/bs.apha.2024.10.004_bib185","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abf4468","article-title":"Sensing low intracellular potassium by NLRP3 results in a stable open structure that promotes inflammasome activation","volume":"7","author":"Tapia-Abell\u00e1n","year":"2021","journal-title":"Science Advances"},{"issue":"3","key":"10.1016\/bs.apha.2024.10.004_bib186","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1227\/01.NEU.0000156715.04900.E6","article-title":"Cerebral oxidative stress and depression of energy metabolism correlate with severity of diffuse brain injury in rats","volume":"56","author":"Tavazzi","year":"2005","journal-title":"Neurosurgery"},{"key":"10.1016\/bs.apha.2024.10.004_bib187","unstructured":"TBI Data. (2024, July 11). Retrieved July 29, 2024, from Traumatic Brain Injury & Concussion website: https:\/\/www.cdc.gov\/traumatic-brain-injury\/data-research\/index.html."},{"issue":"7872","key":"10.1016\/bs.apha.2024.10.004_bib188","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0140-6736(74)91639-0","article-title":"Assessment of coma and impaired consciousness: A practical scale","volume":"304","author":"Teasdale","year":"1974","journal-title":"The Lancet"},{"issue":"17","key":"10.1016\/bs.apha.2024.10.004_bib189","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2018101064","article-title":"Systemic inflammation impairs microglial A\u03b2 clearance through NLRP3 inflammasome","volume":"38","author":"Tejera","year":"2019","journal-title":"The EMBO Journal"},{"issue":"4","key":"10.1016\/bs.apha.2024.10.004_bib190","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1097\/00005072-196310000-00005","article-title":"The fine structure of neurofibrillary tangles in Alzheimer\u2019s disease","volume":"22","author":"Terry","year":"1963","journal-title":"Journal of Neuropathology & Experimental Neurology"},{"issue":"4","key":"10.1016\/bs.apha.2024.10.004_bib191","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.immuni.2009.02.006","article-title":"The intracellular sensor NLRP3 mediates key innate and healing responses to influenza A virus via the regulation of caspase-1","volume":"30","author":"Thomas","year":"2009","journal-title":"Immunity"},{"key":"10.1016\/bs.apha.2024.10.004_bib192","unstructured":"Tobin, O. (2022, December 24). Multiple sclerosis\u2014Symptoms and causes. Retrieved July 1, 2024, from Mayo Clinic website: https:\/\/www.mayoclinic.org\/diseases-conditions\/multiple-sclerosis\/symptoms-causes\/syc-20350269."},{"issue":"8","key":"10.1016\/bs.apha.2024.10.004_bib193","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.tins.2023.05.009","article-title":"The NLRP3 inflammasome and gut dysbiosis as a putative link between HIV-1 infection and ischemic stroke","volume":"46","author":"Torices","year":"2023","journal-title":"Trends in Neurosciences"},{"issue":"9","key":"10.1016\/bs.apha.2024.10.004_bib194","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1136\/jnnp.74.9.1258","article-title":"Effect of a multidisciplinary amyotrophic lateral sclerosis (ALS) clinic on ALS survival: A population based study, 1996\u20132000","volume":"74","author":"Traynor","year":"2003","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"key":"10.1016\/bs.apha.2024.10.004_bib195","article-title":"Weltorganisation f\u00fcr geistiges Eigentum","author":"Tschopp","year":"2002","journal-title":"Patent No. WO0240668A2"},{"issue":"9","key":"10.1016\/bs.apha.2024.10.004_bib196","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.3000354","article-title":"MCC950\/CRID3 potently targets the NACHT domain of wild-type NLRP3 but not disease-associated mutants for inflammasome inhibition","volume":"17","author":"Vande Walle","year":"2019","journal-title":"PLoS Biology"},{"key":"10.1016\/bs.apha.2024.10.004_bib197","unstructured":"Ventyx Biosciences Reports Clinical Data for its NLRP3 Inhibitor Portfolio and Provides Pipeline Updates at Virtual Investor Event. (2024, March 11). Retrieved July 24, 2024, from BioSpace website: https:\/\/www.biospace.com\/ventyx-biosciences-reports-clinical-data-for-its-nlrp3-inhibitor-portfolio-and-provides-pipeline-updates-at-virtual-investor-event."},{"issue":"1","key":"10.1016\/bs.apha.2024.10.004_bib198","first-page":"1","article-title":"NLRP3 expression in mesencephalic neurons and characterization of a rare NLRP3 polymorphism associated with decreased risk of Parkinson\u2019s disease","volume":"4","author":"von Herrmann","year":"2018","journal-title":"Npj Parkinson\u2019s Disease"},{"issue":"1","key":"10.1016\/bs.apha.2024.10.004_bib199","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s12028-017-0378-7","article-title":"Cerebrospinal fluid NLRP3 is increased after severe traumatic brain injury in infants and children","volume":"27","author":"Wallisch","year":"2017","journal-title":"Neurocritical Care"},{"issue":"2","key":"10.1016\/bs.apha.2024.10.004_bib200","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/nrn3638","article-title":"Inflammasomes in the CNS","volume":"15","author":"Walsh","year":"2014","journal-title":"Nature Reviews. Neuroscience"},{"key":"10.1016\/bs.apha.2024.10.004_bib201","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1742-4690-11-35","article-title":"Rapid inflammasome activation in microglia contributes to brain disease in HIV\/AIDS","volume":"11","author":"Walsh","year":"2014","journal-title":"Retrovirology"},{"issue":"2","key":"10.1016\/bs.apha.2024.10.004_bib202","first-page":"931","article-title":"\u03b1-Synuclein promotes progression of Parkinson\u2019s disease by upregulating autophagy signaling pathway to activate NLRP3 inflammasome","volume":"19","author":"Wang","year":"2020","journal-title":"Experimental and Therapeutic Medicine"},{"key":"10.1016\/bs.apha.2024.10.004_bib203","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1186\/s12883-021-02369-4","article-title":"Association between serum NLRP3 and malignant brain edema in patients with acute ischemic stroke","volume":"21","author":"Wang","year":"2021","journal-title":"BMC Neurology"},{"issue":"34","key":"10.1016\/bs.apha.2024.10.004_bib204","doi-asserted-by":"crossref","first-page":"9587","DOI":"10.1073\/pnas.1610099113","article-title":"Caspase-1 causes truncation and aggregation of the Parkinson\u2019s disease-associated protein \u03b1-synuclein","volume":"113","author":"Wang","year":"2016","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"3","key":"10.1016\/bs.apha.2024.10.004_bib205","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1080\/00207454.2019.1679810","article-title":"Adiponectin reduces brain injury after intracerebral hemorrhage by reducing NLRP3 inflammasome expression","volume":"130","author":"Wang","year":"2020","journal-title":"International Journal of Neuroscience"},{"key":"10.1016\/bs.apha.2024.10.004_bib206","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2019.00073","article-title":"The potential role of the NLRP3 inflammasome activation as a link between mitochondria ROS generation and neuroinflammation in postoperative cognitive dysfunction","volume":"13","author":"Wei","year":"2019","journal-title":"Frontiers in Cellular Neuroscience"},{"issue":"6","key":"10.1016\/bs.apha.2024.10.004_bib207","first-page":"34363","article-title":"Cellular and molecular functions of hepatic stellate cells in inflammatory responses and liver immunology","volume":"3","author":"Weiskirchen","year":"2014","journal-title":"Hepatobiliary Surgery and Nutrition"},{"key":"10.1016\/bs.apha.2024.10.004_bib208","unstructured":"WHO EMRO | Stroke, Cerebrovascular accident | Health topics. (n.d.). Retrieved July 29, 2024, from World Health Organization\u2014Regional Office for the Eastern Mediterranean website: http:\/\/www.emro.who.int\/health-topics\/stroke-cerebrovascular-accident\/index.html."},{"issue":"12","key":"10.1016\/bs.apha.2024.10.004_bib209","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1161\/STROKEAHA.118.022001","article-title":"Early prediction of malignant brain edema after ischemic stroke","volume":"49","author":"Wu","year":"2018","journal-title":"Stroke; a Journal of Cerebral Circulation"},{"issue":"7944","key":"10.1016\/bs.apha.2024.10.004_bib210","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/s41586-022-05570-8","article-title":"Cryo-EM structures of the active NLRP3 inflammasome disc","volume":"613","author":"Xiao","year":"2023","journal-title":"Nature"},{"issue":"5","key":"10.1016\/bs.apha.2024.10.004_bib211","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.4049\/jimmunol.1700175","article-title":"Cutting Edge: TRAF6 Mediates TLR\/IL-1R Signaling-Induced Nontranscriptional Priming of the NLRP3 Inflammasome","volume":"199","author":"Xing","year":"2017","journal-title":"Journal of Immunology"},{"key":"10.1016\/bs.apha.2024.10.004_bib212","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107562","article-title":"Characterization of a small molecule inhibitor of the NLRP3 inflammasome and its potential use for acute lung injury","volume":"150","author":"Xu","year":"2024","journal-title":"Bioorganic Chemistry"},{"issue":"6","key":"10.1016\/bs.apha.2024.10.004_bib213","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1080\/13543776.2023.2239502","article-title":"A patent review of NLRP3 inhibitors to treat autoimmune diseases","volume":"33","author":"Xu","year":"2023","journal-title":"Expert Opinion on Therapeutic Patents"},{"issue":"1","key":"10.1016\/bs.apha.2024.10.004_bib214","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1021\/acs.jmedchem.3c01782","article-title":"Design and discovery of novel NLRP3 inhibitors and PET imaging radiotracers based on a 1,2,3-triazole-bearing scaffold","volume":"67","author":"Xu","year":"2024","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/bs.apha.2024.10.004_bib215","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2021.127777","article-title":"Discovery of carbon-11 labeled sulfonamide derivative: A PET tracer for imaging brain NLRP3 inflammasome","volume":"34","author":"Xu","year":"2021","journal-title":"Bioorganic & Medicinal Chemistry Letters"},{"key":"10.1016\/bs.apha.2024.10.004_bib216","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114468","article-title":"Development of sulfonamide-based NLRP3 inhibitors: Further modifications and optimization through structure-activity relationship studies","volume":"238","author":"Xu","year":"2022","journal-title":"European Journal of Medicinal Chemistry"},{"key":"10.1016\/bs.apha.2024.10.004_bib217","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.nbd.2018.05.016","article-title":"Selective NLRP3 inflammasome inhibitor reduces neuroinflammation and improves long-term neurological outcomes in a murine model of traumatic brain injury","volume":"117","author":"Xu","year":"2018","journal-title":"Neurobiology of Disease"},{"issue":"2","key":"10.1016\/bs.apha.2024.10.004_bib218","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/BF00687420","article-title":"Diffuse type of senile plaques in the brains of Alzheimer-type dementia","volume":"77","author":"Yamaguchi","year":"1988","journal-title":"Acta Neuropathologica"},{"issue":"1","key":"10.1016\/bs.apha.2024.10.004_bib219","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.cell.2014.11.047","article-title":"Dopamine controls systemic inflammation through inhibition of NLRP3 inflammasome","volume":"160","author":"Yan","year":"2015","journal-title":"Cell"},{"key":"10.1016\/bs.apha.2024.10.004_bib220","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2020.557170","article-title":"Neuroprotective effect of oridonin on traumatic brain injury via inhibiting NLRP3 inflammasome in experimental mice","volume":"14","author":"Yan","year":"2020","journal-title":"Frontiers in Neuroscience"},{"key":"10.1016\/bs.apha.2024.10.004_bib221","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1016\/j.csbj.2023.03.017","article-title":"Interactions between gut microbes and NLRP3 inflammasome in the gut-brain axis","volume":"21","author":"Yang","year":"2023","journal-title":"Computational and Structural Biotechnology Journal"},{"issue":"9","key":"10.1016\/bs.apha.2024.10.004_bib222","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2013.326","article-title":"Intravenous immunoglobulin suppresses NLRP1 and NLRP3 inflammasome-mediated neuronal death in ischemic stroke","volume":"4","author":"Yang-Wei Fann","year":"2013","journal-title":"Cell Death & Disease"},{"issue":"3","key":"10.1016\/bs.apha.2024.10.004_bib223","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1007\/s12035-017-0467-9","article-title":"NLRP3 inflammasome inhibitor ameliorates amyloid pathology in a mouse model of Alzheimer\u2019s disease","volume":"55","author":"Yin","year":"2018","journal-title":"Molecular Neurobiology"},{"issue":"1","key":"10.1016\/bs.apha.2024.10.004_bib224","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s12868-022-00733-9","article-title":"Spatiotemporal evolution of pyroptosis and canonical inflammasome pathway in hSOD1G93A ALS mouse model","volume":"23","author":"Zhang","year":"2022","journal-title":"BMC Neuroscience"},{"issue":"10","key":"10.1016\/bs.apha.2024.10.004_bib225","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202003937","article-title":"Development of polymeric nanoparticles for blood\u2013brain barrier transfer\u2014strategies and challenges","volume":"8","author":"Zhang","year":"2021","journal-title":"Advanced Science"},{"issue":"3","key":"10.1016\/bs.apha.2024.10.004_bib226","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1002\/mds.26488","article-title":"Cdk5-dependent activation of neuronal inflammasomes in Parkinson\u2019s disease","volume":"31","author":"Zhang","year":"2016","journal-title":"Movement Disorders"},{"issue":"1","key":"10.1016\/bs.apha.2024.10.004_bib227","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-023-01486-5","article-title":"Role of neuroinflammation in neurodegeneration development","volume":"8","author":"Zhang","year":"2023","journal-title":"Signal Transduction and Targeted Therapy"},{"issue":"5","key":"10.1016\/bs.apha.2024.10.004_bib228","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.cell.2015.12.057","article-title":"NF-\u03baB restricts inflammasome activation via elimination of damaged mitochondria","volume":"164","author":"Zhong","year":"2016","journal-title":"Cell"},{"key":"10.1016\/bs.apha.2024.10.004_bib229","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13024-016-0094-3","article-title":"MicroRNA-7 targets Nod-like receptor protein 3 inflammasome to modulate neuroinflammation in the pathogenesis of Parkinson\u2019s disease","volume":"11","author":"Zhou","year":"2016","journal-title":"Molecular Neurodegeneration"},{"issue":"7329","key":"10.1016\/bs.apha.2024.10.004_bib230","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/nature09663","article-title":"A role for mitochondria in NLRP3 inflammasome activation","volume":"469","author":"Zhou","year":"2011","journal-title":"Nature"},{"issue":"6","key":"10.1016\/bs.apha.2024.10.004_bib231","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1097\/00005072-199906000-00002","article-title":"Increased interleukin-1\u03b2 converting enzyme expression and activity in Alzheimer disease","volume":"58","author":"Zhu","year":"1999","journal-title":"Journal of Neuropathology & Experimental Neurology"},{"key":"10.1016\/bs.apha.2024.10.004_bib232","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.bbi.2017.05.014","article-title":"TDP-43 upregulation mediated by the NLRP3 inflammasome induces cognitive impairment in 2 2\u2032,4,4\u2032-tetrabromodiphenyl ether (BDE-47)-treated mice","volume":"65","author":"Zhuang","year":"2017","journal-title":"Brain, Behavior, and Immunity"}],"container-title":["Advances in Pharmacology","Targeting Enzymes in the Brain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1054358924000334?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1054358924000334?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T11:49:12Z","timestamp":1739015352000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1054358924000334"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"ISBN":["9780443342929"],"references-count":232,"URL":"https:\/\/doi.org\/10.1016\/bs.apha.2024.10.004","relation":{},"ISSN":["1054-3589"],"issn-type":[{"value":"1054-3589","type":"print"}],"subject":[],"published":{"date-parts":[[2025]]}}}